Horizon Therapeutics plc Announces New UPLIZNA (inebilizumab-cdon) Data in Neuromyelitis Optica Spectrum Disorder (NMOSD) to be presented at ECTRIMS 2022

-- Presentations will feature analyses from the pivotal Phase 3 study of UPLIZNA, including the relationship between B-cell subsets and NMOSD attacks -- Horizon Therapeutics plc (Nasdaq: HZNP) today

Related Keywords

Ireland ,Neuroimmunol Neuroinflamm ,Orhan Aktas ,Brian Weinshenker ,Tina Ventura ,Hans Peter Hartung ,Ray Gordon ,Rachel Vann ,Instagram ,Product Communications ,Linkedin ,Twitter ,European Commission ,Drug Administration ,Nasdaq ,Facebook ,Research In Multiple Sclerosis ,European Committee For Treatment ,European Committee ,Multiple Sclerosis ,Efficacy Comparison ,First Adjudicated Attack ,Matching Adjusted Indirect Comparison ,Disease Activity ,Receiving Inebilizumab Treatment ,Low Affinity Igg Fc Region Receptor ,Gene Polymorphisms ,Neuromyelitis Optica Spectrum Disorder ,Immunosuppression Treatment ,Hepatitisb Virus ,Progressive Multifocal Leukoencephalopathy ,Full Prescribing Information ,Accessed April ,Scler Relat ,Vice President ,Chief Investor Relations Officer ,Horizon ,Herapeutics ,Nnounces ,Plizna ,Inebilizumab ,Don ,Data ,Euromyelitis ,Voptica ,Spectrum ,Disorder ,Nmosd ,Resented ,Actrims ,022 ,